Page last updated: 2024-10-16

adenine and AIDS, Simian

adenine has been researched along with AIDS, Simian in 85 studies

Research Excerpts

ExcerptRelevanceReference
" The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance."5.35Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. ( Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008)
"Although one animal had a gradual increase in viremia from 3 years onwards, the other 4 tenofovir-treated animals maintained undetectable viremia with occasional viral blips (≤ 300 RNA copies/ml plasma)."3.78Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. ( Abel, K; Canfield, DR; Forthal, DN; Geng, Y; Heneine, W; Jayashankar, K; Johnson, JA; LaBranche, CC; Landucci, G; Lipscomb, J; Montefiori, D; Tarara, RP; Trott, KA; Van Rompay, KK, 2012)
"We reported previously on the emergence and clinical implications of simian immunodeficiency virus (SIVmac251) mutants with a K65R mutation in reverse transcriptase (RT), and the role of CD8+ cell-mediated immune responses in suppressing viremia during tenofovir therapy."3.74Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. ( Bischofberger, N; Blackwood, EJ; Heneine, W; Johnson, JA; Lipscomb, J; Marthas, ML; Matthews, TB; North, TW; Pedersen, NC; Singh, RP; Van Rompay, KK, 2007)
" To explore this possibility, we studied whether CD8(+) cells suppress viremia in four rhesus macaques apparently protected by daily or intermittent Truvada (FTC and tenofovir) during 14 low-dose, rectal SHIV(SF162P3) challenges and during a subsequent drug washout period."3.74Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques. ( Adams, DR; Butera, S; Folks, TM; Garcia-Lerma, JG; Heneine, W; Kersh, EN; Luo, W; Mitchell, J; Otten, RA, 2008)
"The ability of tenofovir to suppress viremia in simian immunodeficiency virus (SIV)-infected macaques for years despite the presence of virulent viral mutants with reduced in vitro susceptibility is unprecedented in this animal model."3.72CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. ( Bischofberger, N; Lawson, JR; Marthas, ML; Pahar, B; Singh, RP; Sodora, DL; Van Rompay, KK; Wingfield, C, 2004)
" The gel also prevents infection in macaques when applied intravaginally or intrarectally prior to challenge with simian-human immunodeficiency virus (SHIV), but very little pharmacokinetic information for macaques is available to help extrapolate the data to humans and thus inform future development activities."1.38Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. ( Allen, P; Kashuba, A; Nuttall, J; Roberts, J; Romano, J; Wang, R; White, N, 2012)
" Despite continued gel dosing postinfection, neither breakthrough infection had evidence of drug resistance by ultrasensitive testing of SHIV in plasma and vaginal lavage."1.38Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. ( Dobard, C; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Novembre, FJ; Pau, CP; Sharma, S; Smith, J, 2012)
" We hypothesized that intermittent prophylactic treatment with long-acting antiviral drugs would be as effective as daily dosing in blocking the earliest stages of viral replication and preventing mucosal transmission."1.36Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. ( Barr, JR; Cong, ME; Folks, TM; García-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Kuklenyik, Z; Lipscomb, J; Martin, A; Masciotra, S; Mitchell, J; Otten, R; Pau, CP; Paxton, L; Youngpairoj, AS; Zheng, Q, 2010)
" Irrespective of the dosing strategy used, the rsIL-7gly administration transiently increased proliferation of both central memory and naive cells, in both CD4(+) and CD8(+) subsets, without increasing SIV levels in the blood."1.36Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses. ( Assouline, B; Axthelm, MK; Legasse, A; Leone, A; Lifson, JD; Morre, M; Okoye, A; Piatak, M; Picker, LJ; Rohankhedkar, M; Sodora, DL; Villinger, F, 2010)
" The likelihood of renal toxicity (proximal renal tubular dysfunction [PRTD]) correlated with plasma drug concentrations, which depended on the dosage regimen and age-related changes in drug clearance."1.35Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. ( Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK, 2008)
" Group 1 was treated subcutaneously with a human-equivalent dose of emtricitabine (FTC), group 2 received orally the human-equivalent dosing of both FTC and tenofovir-disoproxil fumarate (TDF), and group 3 received subcutaneously a similar dosing of FTC and a higher dose of tenofovir."1.35Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. ( Adams, DR; Cong, ME; Delinsky, D; Folks, TM; García-Lerma, JG; Heneine, W; Jackson, E; Janssen, R; Johnson, JA; Kim, C; Lipscomb, J; Luo, W; Masciotra, S; Monsour, M; Otten, RA; Qari, SH; Schinazi, RF, 2008)
"In the treated animal, viremia was controlled to low or undetectable for the study duration, and virus-specific responses remained low."1.33SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy. ( Carruth, LM; Clements, JE; Li, M; Mankowski, JL; Miller, MD; Queen, LA; Shen, A; Siliciano, RF; Tarwater, PM; Zink, MC, 2005)
"Control of off treatment viremia was associated, at least in part, with CD8+ lymphocytes, based on in vivo CD8 depletion studies."1.32Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. ( Bischofberger, N; Blanchard, J; Cline, AN; Lifson, JD; Pandrea, I; Piatak, M; Purcell, J; Rossio, JL; Veazey, RS, 2003)
" Three of four macaques given the same dosing regimen of PMEA had viral load reductions ranging from 1."1.31Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques. ( Bischofberger, N; Crabbs, C; Greenhouse, J; Jiang, JB; Lewis, MG; Racz, K; Racz, P; Silvera, P; Yalley-Ogunro, J, 2000)

Research

Studies (85)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's18 (21.18)18.2507
2000's44 (51.76)29.6817
2010's23 (27.06)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Parker, IK1
Price, KA1
Singletary, T1
Srinivasan, P2
Smith, JM2
Curtis, KA2
Perez, S1
Johnson, AM1
Xiang, SH1
Li, J1
Foley, BT1
Doyle-Meyers, L1
Panganiban, A1
Kaur, A1
Veazey, RS2
Wu, Y1
Ling, B1
Cong, ME8
Mitchell, J6
Sweeney, E1
Bachman, S1
Hanson, DL5
Heneine, W15
García-Lerma, JG11
Amancha, PK1
Hong, JJ1
Rogers, K1
Ansari, AA2
Villinger, F4
Teller, RS1
Lo, Y1
Dinh, CT1
Kiser, PF1
Herold, BC1
Massud, I1
Babusis, D2
Deyounks, F1
Ray, AS4
Rooney, JF2
Miller, MD4
Van Rompay, KK16
Durand-Gasselin, L1
Brignolo, LL2
Abel, K3
Cihlar, T1
Spinner, A2
Jerome, C1
Moore, J1
Kearney, BP2
Marthas, ML15
Reiser, H1
Bischofberger, N29
Cranage, M1
Sharpe, S1
Herrera, C1
Cope, A1
Dennis, M1
Berry, N1
Ham, C1
Heeney, J3
Rezk, N1
Kashuba, A2
Anton, P1
McGowan, I1
Shattock, R1
Kubo, M1
Nishimura, Y1
Shingai, M1
Lee, W1
Brenchley, J1
Lafont, B1
Buckler-White, A1
Igarashi, T1
Martin, MA1
Parikh, UM1
Dobard, C3
Sharma, S3
Jia, H1
Martin, A4
Pau, CP4
Guenthner, P1
Smith, J3
Kersh, E2
Novembre, FJ2
Otten, R2
Folks, T2
Lewis, MG5
Norelli, S2
Collins, M2
Barreca, ML2
Iraci, N2
Chirullo, B2
Yalley-Ogunro, J4
Greenhouse, J4
Titti, F1
Garaci, E1
Savarino, A2
Youngpairoj, AS5
Zheng, Q4
Masciotra, S2
Kuklenyik, Z2
Holder, A3
Lipscomb, J6
Barr, JR1
Paxton, L2
Folks, TM4
Leone, A1
Rohankhedkar, M1
Okoye, A1
Legasse, A1
Axthelm, MK1
Piatak, M5
Lifson, JD10
Assouline, B1
Morre, M1
Picker, LJ1
Sodora, DL3
Aung, W2
Kuklenyik, S1
Luo, W4
Lin, CY1
Lee, WA2
Kennedy, MS1
Luckay, A1
Hanson, D2
Owen, SM1
Lugli, E1
Mueller, YM1
Katsikis, PD1
Roederer, M1
Nuttall, J1
Wang, R1
White, N1
Allen, P1
Roberts, J1
Romano, J1
Murphey-Corb, M3
Rajakumar, P1
Michael, H1
Nyaundi, J1
Didier, PJ1
Reeve, AB1
Mitsuya, H1
Sarafianos, SG1
Parniak, MA1
Shytaj, IL1
Della Corte, A1
Acosta, EP1
Kersh, EN2
Adams, DR4
Butler, K1
Hendry, RM1
McNicholl, JM1
Abbott, Z1
Geng, Y2
Jayashankar, K2
Johnson, JA5
Trott, KA1
LaBranche, CC1
Landucci, G1
Tarara, RP6
Canfield, DR6
Forthal, DN1
Montefiori, D1
Nakasone, T1
Murakami, T1
Yamamoto, N1
Jasny, E1
Geer, S1
Frank, I1
Vagenas, P1
Aravantinou, M1
Salazar, AM1
Gettie, A2
Blanchard, JL1
Robbiani, M1
Schmidt, KA3
Lawson, JR4
Singh, R1
Castillo, AB1
Tarantal, AF2
Watnik, MR1
Martin, RB1
Cline, AN1
Rossio, JL3
Purcell, J1
Pandrea, I1
Blanchard, J1
Cohen, J4
Singh, RP4
Pahar, B2
Wingfield, C1
Shen, L2
Shen, Y2
Huang, D1
Qiu, L1
Sehgal, P2
Du, GZ1
Letvin, NL2
Chen, ZW2
George, MD1
Reay, E1
Sankaran, S2
Dandekar, S3
Carruth, LM2
Zink, MC2
Tarwater, PM1
Li, M2
Queen, LA1
Mankowski, JL2
Shen, A1
Siliciano, RF1
Clements, JE2
Gama, L1
Bullock, B1
Fuller, DH2
Rajakumar, PA2
Wu, MS1
McMahon, CW1
Shipley, T1
Fuller, JT1
Bazmi, A1
Trichel, AM2
Allen, TM1
Mothe, B1
Haynes, JR1
Watkins, DI1
Montefiori, DC1
Sexton, JJ1
Colón, R1
Blackwood, EJ2
Taber, R1
Dowling, P1
Meleason, D1
Amedee, A1
Grant, RM1
Wainberg, MA1
Subbarao, S2
Otten, RA4
Ramos, A2
Kim, C3
Jackson, E2
Monsour, M3
Bashirian, S1
Johnson, J1
Soriano, V1
Rendon, A1
Hudgens, MG1
Butera, S3
Janssen, R2
Greenberg, AE1
Cervasi, B1
Paiardini, M1
Serafini, S1
Fraternale, A1
Menotta, M1
Engram, J1
Lawson, B1
Staprans, SI1
Piedimonte, G1
Perno, CF1
Silvestri, G1
Magnani, M1
Metzner, KJ1
Binley, JM1
Marx, P1
Nixon, DF1
Connor, RI1
Uberla, K2
Rosenwirth, B2
Ten Haaft, P2
Sutter, G1
Erfle, V1
Matthews, TB1
Pedersen, NC7
North, TW1
Verhoeven, D1
Adams, D1
Qari, SH1
Delinsky, D1
Schinazi, RF1
McCarthy, M1
Tsai, CC5
Follis, KE5
Sabo, A3
Beck, TW3
Grant, RF2
Benveniste, RE3
Black, R1
Grant, R1
Bartz, C1
Nolte, RE1
Cherrington, JM4
Berardi, CJ3
Mulato, AS1
Telm, S1
Joag, SV1
Li, Z2
Foresman, L3
Pinson, DM1
Stephens, EB1
Raghavan, R1
Navé, JF1
Casara, P1
Narayan, O3
Nowak, MA3
Lloyd, AL1
Vasquez, GM2
Wiltrout, TA1
Wahl, LM1
Williams, J1
Kinter, A1
Fauci, AS1
Hirsch, VM3
Emau, P2
Morton, WR2
Agatep, E1
Dehqanzada, ZA1
Cundy, KC1
Aguirre, NL4
Lietman, PS1
Dailey, PJ3
Lamy, PD2
Shaw, JP1
Cundy, K1
Mattapallil, JJ1
Smit-McBride, Z1
Dailey, P1
Bogers, WM1
Nieuwenhuis, IG1
Niphuis, H2
Kuhn, EM1
Heeney, JL1
Margot, NA1
Arnaout, R1
Li, L2
Parks, TL1
Schneider, DK1
Kiser, RF1
Coalter, VJ1
Walsh, G1
Imming, RJ1
Fisher, B2
Flynn, BM2
Wodarz, D3
Silvera, P2
Racz, P2
Racz, K1
Crabbs, C2
Jiang, JB1
Wick, D1
Self, SG1
Smith, MS1
Lopez, GJ1
Tsay, J1
Page, A1
Wang, C1
Adany, I1
Buch, S2
Sun, JC1
Tran, CA1
Lori, F1
Xu, J1
Varga, G1
Zinn, DE1
Wagner, W1
Tinelli, C1
Lisziewicz, J1
Kumar, A1
Spring, M1
Stahl-Hennig, C1
Stolte, N1
Tenner-Ràcz, K1
Lorenzen, D1
Hunsmann, G1
Dittmer, U1
James, JS1
McChesney, MB1
Zhou, D1
Simon, M1
Miller, M1
Enimi, EA1
Henckler, B1
Chalifoux, L1
Sehgal, N1
Gastron, M1
Parks, T1
Kiser, R1
Coalter, V1
Czajak, S1
Reimann, KA1
Schmitz, JE1
Ghrayeb, J1
Desrosiers, RC1
Brice, GT1
Mayne, AE1
Bostik, P1
Mori, K1
June, CH1
Balzarini, J1
Naesens, L1
Slachmuylders, J1
Rosenberg, I1
Holý, A1
Schellekens, H1
De Clercq, E1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Expanded Safety Investigation of Tenofovir 1% Gel in Pregnancy and Lactation[NCT01136759]Phase 1232 participants (Actual)Interventional2011-03-31Completed
HIV Pre-Exposure Prophylaxis Priming of Immune Effectors[NCT02593409]Phase 4220 participants (Anticipated)Interventional2017-05-25Recruiting
The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection[NCT03205566]Phase 438 participants (Actual)Interventional2017-09-19Completed
A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV)[NCT01214759]Phase 4103 participants (Actual)Interventional2011-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Adverse Events Based on PE, Blood Test and Event Reporting on Raltegravir Based PrEP, in HIV Negative Individuals

Subject safety and tolerability will be determined by physical examination, blood tests and adverse event reporting. FBC, U&E and LFTs will be carried out at baseline and thereafter as symptom directed. Adverse event review. If significant adverse events have been reported, these will be clinically followed in accordance to the instruction of the study physician. (NCT03205566)
Timeframe: Through Study completion, an average of 55 days

InterventionAdverse event (Number)
Arm A Raltegravir12
Arm B Raltegravir Lamivudine15

The Level of Raltegravir Alone or Raltegravir /Lamivudine Required in the Plasma, Vagina and Rectum for 100% ex Vivo Protection From HIV

"The level of Raltegravir alone or Raltegravir /lamivudine required in the plasma, vagina and rectum for 100% ex vivo protection from HIV .~High viral dose challenge: ex vivo challenge of tissue with 104 TCID50/mL HIV-1BaL Low viral dose challenge: ex vivo challenge of tissue with 102 TCID50/mL HIV-1BaL" (NCT03205566)
Timeframe: Through Study completion, an average of 55 days

,,
Interventionng/mL (Mean)
Plasma: High Dose Challenge in rectal tissuePlasma: Low viral dose challenge in rectal tissueRectal: high viral dose challenge in rectal tissueRectal: Low viral dose challenge in rectal tissuePlasma: high viral dose challenge in vaginal tissuPlasma: low viral dose challenge in vaginal tissuePlasma: high dose in vaginal tissuePlasma: low dose in vaginal tissue
Lamivudine During Combination Treatment265.10265.101722.021722.02266.40169.101557.801437.80
RaltegravirNA979.8NA729.36NA979.8NA607.60
Raltegravir During Combination Treatment669.90669.90862.35862.35828.60281.60648.24273.02

The Time From First Dose of Drug to Maximum Mucosal ex Vivo Protection From HIV.

Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed. (NCT03205566)
Timeframe: Up to 7 days from first dose

InterventionDays (Mean)
Time from first dose of drug to maximum rectal ex vivo protection from high titer HIV infectionTime from first dose of drug to maximum rectal ex vivo protection from low titer HIV infectionTime from first dose of drug to maximum vaginal ex vivo protection from low titer HIV infection
Raltegravir322.673

The Time From First Dose of Drug to Maximum Mucosal ex Vivo Protection From HIV.

Time in days from first receipt of antiretroviral (Raltegravir 400mg +/-lamivudine) until maximal ex vivo protection (against high or low titre of HIV-1BaL) was observed. (NCT03205566)
Timeframe: Up to 7 days from first dose

InterventionDays (Mean)
Time from first dose of drug to maximum rectal ex vivo protection from low titer HIV infectionTime from first dose of drug to maximum rectal ex vivo protection from High titer HIV infectionTime from first dose of drug to maximum vaginal ex vivo protection from low titer HIV infection
Raltegravir Lamivudine2233.67

The Time to Cessation of Mucosal ex Vivo Protection From HIV After Stopping ART at Steady State.

Time in days from stopping antiretroviral (Raltegravir 400mg +/-lamivudine) until ex vivo protection (against high or low viral titre of HIV-1BaL) was no longer observed. (NCT03205566)
Timeframe: 5 days post last dose

,
InterventionDays (Mean)
Time to cessation of rectal ex vivo protection from high HIV dose challenge post ART at steady stateTime to cessation of rectal ex vivo protection from low HIV dose challenge post ART at steady stateTime to cessation of vaginal ex vivo protection from high HIVdose challenge post ART at steady stateTime to cessation of vaginal ex vivo protection from low HIV dose challenge post ART at steady state
Raltegravir3.33NA45
Raltegravir LamivudineNANANANA

Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months

This measure assesses whether the combination of Truvada and Raltegravir prevents the acquisition of HIV at six months among HIV-negative people who have been exposed to HIV. (NCT01214759)
Timeframe: 6 months

Interventionparticipants (Number)
Truvada and Raltegravir0

Safety and Tolerability as Assessed by the Number of Participants Who Completed the 28-day Course of the Antiretroviral Drugs Being Explored in This Study

(NCT01214759)
Timeframe: 28 days

Interventionparticipants (Number)
Truvada and Raltegravir85

Other Studies

85 other studies available for adenine and AIDS, Simian

ArticleYear
A multiplex assay for detection of SHIV plasma and mucosal IgG and IgA.
    Journal of immunological methods, 2017, Volume: 450

    Topics: Adenine; Adenoviruses, Simian; Administration, Intravaginal; Animals; Anti-HIV Agents; Biomarkers; D

2017
Persistence of SIV in the brain of SIV-infected Chinese rhesus macaques with or without antiretroviral therapy.
    Journal of neurovirology, 2018, Volume: 24, Issue:1

    Topics: Adenine; Amino Acid Sequence; Animals; Antiretroviral Therapy, Highly Active; Basal Ganglia; Brain S

2018
Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
    The Journal of infectious diseases, 2013, Aug-01, Volume: 208, Issue:3

    Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Deoxycytidine; Disease Transmission, Infect

2013
In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit.
    Journal of immunology (Baltimore, Md. : 1950), 2013, Dec-15, Volume: 191, Issue:12

    Topics: Adenine; Animals; Anti-Retroviral Agents; Antibodies, Monoclonal; Apoptosis; CD4-Positive T-Lymphocy

2013
Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures.
    Journal of acquired immune deficiency syndromes (1999), 2015, Jan-01, Volume: 68, Issue:1

    Topics: Adenine; Animals; Anti-HIV Agents; Delayed-Action Preparations; Female; HIV Infections; Macaca nemes

2015
Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.
    The Journal of infectious diseases, 2016, 10-01, Volume: 214, Issue:7

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Emtricitabine; Macaca; Simian Acquired

2016
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9

    Topics: Adenine; Age Factors; Animals; Anti-HIV Agents; Disease Models, Animal; Female; HIV Infections; HIV-

2008
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    PLoS medicine, 2008, Aug-05, Volume: 5, Issue:8

    Topics: Adenine; Animals; Anti-Infective Agents, Local; Antibody Formation; Cross-Priming; Gels; HeLa Cells;

2008
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    PLoS medicine, 2008, Aug-05, Volume: 5, Issue:8

    Topics: Adenine; Animals; Anti-Infective Agents, Local; Antibody Formation; Cross-Priming; Gels; HeLa Cells;

2008
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    PLoS medicine, 2008, Aug-05, Volume: 5, Issue:8

    Topics: Adenine; Animals; Anti-Infective Agents, Local; Antibody Formation; Cross-Priming; Gels; HeLa Cells;

2008
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
    PLoS medicine, 2008, Aug-05, Volume: 5, Issue:8

    Topics: Adenine; Animals; Anti-Infective Agents, Local; Antibody Formation; Cross-Priming; Gels; HeLa Cells;

2008
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
    Journal of virology, 2009, Volume: 83, Issue:14

    Topics: Adenine; Amino Acid Sequence; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured;

2009
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
    Journal of virology, 2009, Volume: 83, Issue:20

    Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combin

2009
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
    Retrovirology, 2010, Mar-16, Volume: 7

    Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Coun

2010
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.
    Science translational medicine, 2010, Jan-13, Volume: 2, Issue:14

    Topics: Adenine; Administration, Oral; Animals; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir D

2010
Increased CD4+ T cell levels during IL-7 administration of antiretroviral therapy-treated simian immunodeficiency virus-positive macaques are not dependent on strong proliferative responses.
    Journal of immunology (Baltimore, Md. : 1950), 2010, Aug-01, Volume: 185, Issue:3

    Topics: Adenine; Animals; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Po

2010
More research needed to find new HIV-suppressive functions of cytotoxic T cells.
    Immunotherapy, 2010, Volume: 2, Issue:2

    Topics: Adenine; Animals; Combined Modality Therapy; Deoxycytidine; Emtricitabine; HIV Infections; Humans; L

2010
Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.
    Virology, 2011, Apr-10, Volume: 412, Issue:2

    Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Resistance, Viral; Em

2011
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
    Journal of virology, 2011, Volume: 85, Issue:13

    Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Deoxyadenine Nucleotides; HIV Infections; HIV Re

2011
Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis.
    Journal of acquired immune deficiency syndromes (1999), 2011, Aug-15, Volume: 57, Issue:5

    Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Deoxy

2011
IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.
    Blood, 2011, Sep-01, Volume: 118, Issue:9

    Topics: Adaptive Immunity; Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active;

2011
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1

    Topics: Adenine; Administration, Intravaginal; Administration, Rectal; Animals; Antiviral Agents; Area Under

2012
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
    Journal of virology, 2012, Volume: 86, Issue:2

    Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; Drug Stability; Female; Half-Life; HIV Infection

2012
Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:9

    Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; Deoxyadenosines; Deoxycytidine; Emtricitabine;

2012
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
    PLoS pathogens, 2012, Volume: 8, Issue:6

    Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; D

2012
Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis.
    The Journal of infectious diseases, 2012, Sep-01, Volume: 206, Issue:5

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytoki

2012
Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:9

    Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Drug Administration Schedule; Injections,

2012
Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
    Retrovirology, 2012, Jul-17, Volume: 9

    Topics: Adenine; Alleles; Animals; Antibodies, Viral; Antibody Formation; Antiviral Agents; CD4 Lymphocyte C

2012
Double oral administration of emtricitabine/tenofovir prior to virus exposure protects against highly pathogenic simian/human immunodeficiency virus infection in macaques.
    Japanese journal of infectious diseases, 2012, Volume: 65, Issue:4

    Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Antibiotic Prophylaxis; CD4 Lymphocyte Coun

2012
Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2012, Dec-01, Volume: 61, Issue:4

    Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtr

2012
Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.
    The Journal of infectious diseases, 2002, Nov-15, Volume: 186, Issue:10

    Topics: Adenine; Administration, Topical; Animals; Anti-HIV Agents; Disease Models, Animal; Macaca; Organoph

2002
Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta).
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2002, Volume: 20, Issue:6

    Topics: Adenine; Animals; Bone Remodeling; Calcification, Physiologic; Macaca mulatta; Organophosphonates; O

2002
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
    Journal of medical primatology, 2003, Volume: 32, Issue:4-5

    Topics: Adenine; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA Primers; Gene Products, env; Gene

2003
Cambodia: can a drug provide some protection?
    Science (New York, N.Y.), 2003, Sep-19, Volume: 301, Issue:5640

    Topics: Adenine; Animals; Anti-HIV Agents; Cambodia; Controlled Clinical Trials as Topic; Female; Haplorhini

2003
CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
    Journal of virology, 2004, Volume: 78, Issue:10

    Topics: Adenine; Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Macaca mulatta; Organophosphonates;

2004
The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
    Journal of acquired immune deficiency syndromes (1999), 2004, Aug-01, Volume: 36, Issue:4

    Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; CD4-Positive T-Lymphocytes;

2004
Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells.
    The Journal of infectious diseases, 2004, Oct-15, Volume: 190, Issue:8

    Topics: Adenine; Amino Acid Sequence; Animals; Cattle; CD4-Positive T-Lymphocytes; Disease Models, Animal; D

2004
Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration.
    Journal of virology, 2005, Volume: 79, Issue:5

    Topics: Adenine; Animals; Anti-Retroviral Agents; Antibody Formation; Antigen Presentation; CD4-Positive T-L

2005
SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy.
    Journal of medical primatology, 2005, Volume: 34, Issue:3

    Topics: Adenine; Animals; Anti-Retroviral Agents; Drug Therapy, Combination; Emtricitabine; Immunity, Cellul

2005
The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy.
    Journal of neurovirology, 2005, Volume: 11, Issue:2

    Topics: Adenine; Animals; Anti-HIV Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; D

2005
DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued.
    Virology, 2006, Apr-25, Volume: 348, Issue:1

    Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cell Proliferat

2006
Retrovirus meeting. Novel attacks on HIV move closer to reality.
    Science (New York, N.Y.), 2006, Feb-17, Volume: 311, Issue:5763

    Topics: Adenine; Animals; Anti-HIV Agents; Evolution, Molecular; HIV Infections; HIV-1; Humans; Organic Chem

2006
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
    Journal of virology, 2006, Volume: 80, Issue:13

    Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Biomarkers; Drug Resistance, Viral; Immune Tole

2006
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 43, Issue:1

    Topics: Adenine; Administration, Oral; Administration, Topical; Alanine; Animals; Anti-HIV Agents; Genetic P

2006
Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate.
    Virology, 2006, Oct-10, Volume: 354, Issue:1

    Topics: Adenine; Amino Acid Sequence; Animals; Antiviral Agents; Drug Resistance, Viral; Evolution, Molecula

2006
Chemoprophylaxis of HIV infection: moving forward with caution.
    The Journal of infectious diseases, 2006, Oct-01, Volume: 194, Issue:7

    Topics: Adenine; Animals; Antiviral Agents; Chemoprevention; Disease Models, Animal; HIV Infections; HIV-1;

2006
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
    The Journal of infectious diseases, 2006, Oct-01, Volume: 194, Issue:7

    Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Drug Resistance, Viral;

2006
Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.
    Journal of virology, 2006, Volume: 80, Issue:21

    Topics: Adenine; Animals; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cercocebus atys; Drug Car

2006
Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
    Retrovirology, 2006, Dec-21, Volume: 3

    Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; CD8-Positive T-Lymphocytes; Chronic Disease; D

2006
Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.
    Journal of medical primatology, 2007, Volume: 36, Issue:1

    Topics: Adenine; Animals; Anti-Retroviral Agents; Antibodies, Viral; Fusion Proteins, gag-pol; Genetic Vecto

2007
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
    Retrovirology, 2007, Apr-06, Volume: 4

    Topics: Adenine; Amino Acid Substitution; Animals; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Disease Mode

2007
Simian immunodeficiency virus infection induces severe loss of intestinal central memory T cells which impairs CD4+ T-cell restoration during antiretroviral therapy.
    Journal of medical primatology, 2007, Volume: 36, Issue:4-5

    Topics: Adenine; Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Di

2007
Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention.
    Journal of medical primatology, 2007, Volume: 36, Issue:4-5

    Topics: Adenine; Administration, Rectal; Animals; Anti-HIV Agents; Antibodies, Viral; Chemoprevention; Disea

2007
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.
    PLoS medicine, 2008, Volume: 5, Issue:2

    Topics: Adenine; Animals; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Macaca; Macaca mulatta

2008
Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:4

    Topics: Adenine; Animals; Anti-HIV Agents; Antibodies; Antibody Specificity; Antiviral Agents; CD8-Positive

2008
Drug prevents SIV infection.
    Lancet (London, England), 1995, Dec-02, Volume: 346, Issue:8988

    Topics: Adenine; Animals; Antiviral Agents; Macaca fascicularis; Organophosphonates; Organophosphorus Compou

1995
AIDS research. New drug shows promise in monkeys.
    Science (New York, N.Y.), 1995, Nov-17, Volume: 270, Issue:5239

    Topics: Adenine; Animals; Antiviral Agents; HIV; HIV Infections; Humans; Infectious Disease Transmission, Ve

1995
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
    Science (New York, N.Y.), 1995, Nov-17, Volume: 270, Issue:5239

    Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Base Sequence; Cells, Cultured; HIV Infection

1995
Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques.
    The Journal of infectious diseases, 1995, Volume: 171, Issue:5

    Topics: Adenine; Animals; Antiviral Agents; Chronic Disease; DNA, Viral; Leukocytes, Mononuclear; Lymphocyte

1995
Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques.
    The Journal of infectious diseases, 1994, Volume: 169, Issue:2

    Topics: Adenine; Animals; Antibodies, Viral; Base Sequence; DNA Primers; DNA, Viral; Dose-Response Relations

1994
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
    Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:11

    Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Drug Resistance; Immunoglobu

1996
Early treatment with 9-(2-phosphonylmethoxyethyl)adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques.
    AIDS research and human retroviruses, 1997, Feb-10, Volume: 13, Issue:3

    Topics: Adenine; Animals; Antiviral Agents; Macaca mulatta; Organophosphonates; Simian Acquired Immunodefici

1997
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.
    Journal of virology, 1997, Volume: 71, Issue:10

    Topics: Adenine; AIDS Vaccines; Animals; Antiviral Agents; Cells, Cultured; Humans; Kinetics; Lymphocytes; M

1997
Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment.
    Journal of virology, 1998, Volume: 72, Issue:5

    Topics: Adenine; Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Adm

1998
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
    AIDS research and human retroviruses, 1998, Jun-10, Volume: 14, Issue:9

    Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Cesarean Section; Chimera; D

1998
Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.
    AIDS (London, England), 1998, Jun-18, Volume: 12, Issue:9

    Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; Dose-Response Relationship,

1998
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
    Journal of virology, 1999, Volume: 73, Issue:4

    Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Humans; Injections, Subcutaneous; Macaca mulatt

1999
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1999, Apr-01, Volume: 20, Issue:4

    Topics: Adenine; Animals; Animals, Newborn; Antiviral Agents; Biological Transport; Body Weight; Female; Imm

1999
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
    Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:4

    Topics: Adenine; Animals; Animals, Newborn; Antiviral Agents; Macaca; Mutation; Organophosphonates; Organoph

1999
Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2.
    Journal of virology, 1999, Volume: 73, Issue:8

    Topics: Adenine; Animals; Antiviral Agents; CD11 Antigens; CD4-Positive T-Lymphocytes; Cell Division; Immuno

1999
Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
    Journal of virology, 2000, Volume: 74, Issue:4

    Topics: Adenine; Animals; Anti-HIV Agents; Cells, Cultured; HIV Envelope Protein gp120; HIV Reverse Transcri

2000
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
    Journal of virology, 2000, Volume: 74, Issue:4

    Topics: Adenine; Administration, Oral; Animals; Animals, Newborn; Antiviral Agents; Macaca mulatta; Organoph

2000
Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.
    Journal of virology, 2000, Volume: 74, Issue:6

    Topics: Adenine; Animals; Antiviral Agents; Female; Macaca mulatta; Organophosphonates; Organophosphorus Com

2000
Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.
    AIDS research and human retroviruses, 2000, May-20, Volume: 16, Issue:8

    Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; Antiviral Agents; Lymph Nodes; Macaca mulatta;

2000
Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
    Mathematical biosciences, 2000, Volume: 165, Issue:2

    Topics: Adenine; Animals; Anti-HIV Agents; Computer Simulation; Disease Progression; HIV; HIV Infections; Hu

2000
Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.
    Virology, 2000, Nov-25, Volume: 277, Issue:2

    Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Cerebrospinal Fluid; Disease Models, Animal

2000
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.
    Journal of medical primatology, 2000, Volume: 29, Issue:3-4

    Topics: Adenine; Animals; Disease Models, Animal; DNA, Viral; HIV Infections; Humans; Infectious Disease Tra

2000
Control of SIV rebound through structured treatment interruptions during early infection.
    Science (New York, N.Y.), 2000, Nov-24, Volume: 290, Issue:5496

    Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-

2000
Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
    Virology, 2001, Jan-05, Volume: 279, Issue:1

    Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; Disease Models, Animal; HIV Antibodies; HIV In

2001
Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.
    Virology, 2001, Jan-05, Volume: 279, Issue:1

    Topics: Adenine; Animals; Anti-HIV Agents; Apoptosis; CD8-Positive T-Lymphocytes; Disease Models, Animal; Hu

2001
PMPA beats SIV again.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:5

    Topics: Adenine; Anemia; Animals; Antiviral Agents; Hemoglobins; Macaca; Organophosphonates; Phosphates; Sim

1996
PMPA--first human results.
    AIDS treatment news, 1997, Apr-18, Issue:No 269

    Topics: Adenine; Animals; Antiviral Agents; Clinical Trials as Topic; Haplorhini; HIV; HIV Infections; Human

1997
Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
    The Journal of infectious diseases, 2001, Aug-15, Volume: 184, Issue:4

    Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; DNA, Viral; Humans; Lymphocyte Activation; Mac

2001
Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
    Journal of virology, 2001, Volume: 75, Issue:18

    Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; HIV Protease Inhibitors; Indinavir; Macaca mula

2001
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.
    Journal of virology, 2001, Volume: 75, Issue:21

    Topics: Adenine; Animals; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Female; Macaca mulatta; Organophospho

2001
Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.
    Blood, 2002, Jan-15, Volume: 99, Issue:2

    Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Blood Transfusion, Autologous; CD4-Positive T

2002
Vaccines. Monkey puzzles.
    Science (New York, N.Y.), 2002, Jun-28, Volume: 296, Issue:5577

    Topics: Acquired Immunodeficiency Syndrome; Adenine; AIDS Vaccines; Animals; Anti-HIV Agents; Clinical Trial

2002
9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys.
    AIDS (London, England), 1991, Volume: 5, Issue:1

    Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Blotting, Western; Cell Line; HIV Envelope Pr

1991